Karlsson, M.O.

patient model group docetaxel irinotecan clearance pharmacokinetic lf abnormalities liver parameter abnormality cancer study docetaxel clearance function variant population ermbt variability ugt 1a table concentration covariate plasma value analysis -38 cyp 3a activity polymorphism activity erythromycin breath test treatment number allele binding model variant type patient effect liver function irinotecan disposition toxicity bilirubin grade group 3 b liver impairment neutropenia sn -38 metabolism genotype 2002. phosphatase result transporter figure pharmacogenetic lactone impairment disposition pharmacokinetic parameters 40  mg /m metabolite population pharmacokinetic model enzyme liver function abnormalities protein binding error degree nonmem lf tests volume infusion breath frequency group 3 interindividual association variation 350 mg /m 75  mg /m aag − aag